Chris Rao, is the Director of Clinical Trials at Lubris Biopharma. Chris has 14 years of experience in clinical research, with proficiency in a wide range of indications including oncology, supportive care, medical devices, and dermatology. Chris plays a leading role in overseeing strategy and execution of all Lubris’s clinical trials. He is also an experienced clinical trial project manager, with expertise in study design, monitoring, regulatory matters, and data management.
Prior to his time at Lubris, Chris previously served as Associate Director at a niche oncology CRO, Clinical Assistance Programs (CAP). Prior to joining CAP, Chris worked as an analyst at Stone-Crowne Associates, performing pharmaceutical marketing data analysis for clients such as Johnson & Johnson as well as financial analysis for MIT and Harvard University
Xavier GOBERT / CEO : Xavier Gobert is a respected and dedicated data professional.
He has a record of more than 25 Years’ experience in the Pharmaceutical Industry. He is a passionate clinical data standards expert leading the French Users Group of CDISC since 2011.
He successfully operated in multicultural teams in big pharmaceutical organizations as well as IT and clinical services providers. Xavier has a deep knowledge of EMA and FDA regulations. He is certified in Data Protection and currently DPO for 10 U.S. based companies
James L. Sherley, M.D., Ph.D. is the founder, President, and CEO of Massachusetts stem cell biotechnology company Asymmetrex, LLC. Asymmetrex develops and markets technologies for advancing stem cell medicine, including the first method achieving specific and accurate certification of the dosage of therapeutic tissue stem cells, called kinetic stem cell (KSC) counting. Asymmetrex’s kinetic stem cell counting platforms are also used to optimize manufacturing of therapeutic stem cells and for evaluations of drug effects on tissue stem cells. Dr. Sherley is a graduate of Harvard College, with a B.A. degree in biology, and the Johns Hopkins University School of Medicine, earning joint M.D. and Ph.D. degrees. Prior to founding Asymmetrex, he held academic research appointments at the Fox Chase Cancer Center, Massachusetts Institute of Technology, and Boston Biomedical Research Institute. Dr. Sherley’s professional awards include Pew Biomedical Research Scholar, Ellison Medical Foundation Senior Scholar in Aging Research, and NIH Director’s Pioneer Award.
Laurie brings over 20 years of experience and roles ranging from clinical study coordinator, to clinical research associate (CRA), followed by a progression to Operations Head and Franchise Leader. Her therapeutically aligned operational experience includes leading large Phase III global clinical trials as well as small-scale early phase clinical trials testing small molecule and large molecule therapies. She was the Program Director for global Phase III cardiovascular trials encompassing 38 countries across 620 sites, including 3,400 patients, and other trials involving complex and rare diseases. Her responsibilities have spanned the full duration of studies, from start-up to project close-out and review
